The cloud-based personalized medicine software company will stay in Cambridge, Massachusetts and will become a wholly-owned subsidiary of the institute.
Researchers have released new tools for analyzing epigenomic data as part of the International Human Epigenome Consortium.
Early backers can get their genome or exome sequenced at discounted rates of $999 and $399, respectively, limited to the first 10 and 50 users in each case.
The web-based gene analysis software is now implemented on IU's NCGAS resources and will soon be running on hardware at other XSEDE network sites.
DSysMap combines mutation information with protein interaction data to provide a clearer picture of functional changes associated with the development of complex diseases.
The Sanger Institute spin-off will use its sequencing and bioinformatics services to link genomic and clinical outcomes data for patient stratification.
MTTC links up with iBridge Network; ViroStatics licenses compound library from University of Siena; Ben-Gurion University inks research pact with Bayer CropScience, and more …
The vendors hope to help customers obtain funding from a new program called NIH Challenge Grants, which will set aside between $100 million and $200 million, and the National Centers for Research Resources, which will get an additional $300 million.
Direct-to-consumer genetic testing companies have based their products on what scientists have accomplished, but the caveat is that the science is still in its early days.
A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.
Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.
In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.
A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.